<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187599</url>
  </required_header>
  <id_info>
    <org_study_id>SEC-P012019-CRT100</org_study_id>
    <nct_id>NCT04187599</nct_id>
  </id_info>
  <brief_title>Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)</brief_title>
  <official_title>Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D) Rigid Gas Permeable Contact Lenses for Corneal Refractive Therapy for Temporary Myopic Refractive Power Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paragon Vision Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TigerMed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Paragon Vision Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this post market clinical study is to evaluate the effectiveness and
      safety of the Paragon CRT®100 Contact Lens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study has two phases: prospective and retrospective.

      Prospective Phase - evaluates the post-market long-term effectiveness and safety of the
      Paragon CRT® 100 Contact Lenses, for temporary myopic refractive power reduction with minimum
      12-month period follow-up.

      Retrospective phase - evaluates the post-market long-term safety of the Paragon CRT® 100
      Contact Lenses, for temporary myopic refractive power reduction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, open label, 12 month follow up study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>product effectiveness</measure>
    <time_frame>1 month</time_frame>
    <description>Effectiveness=number of eyes with both uncorrected visual acuity and dioptric power meet the &quot;effective&quot; standards/total number of eyes evaluated*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>uncorrected visual acuity</measure>
    <time_frame>At baseline</time_frame>
    <description>Use standard LogMAR chart to measure the distant uncorrected visual acuity. Use 5.0 system to record LogMAR visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>uncorrected visual acuity</measure>
    <time_frame>1 day</time_frame>
    <description>Use standard LogMAR chart to measure the distant uncorrected visual acuity. Use 5.0 system to record LogMAR visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>uncorrected visual acuity</measure>
    <time_frame>At 1 week</time_frame>
    <description>Use standard LogMAR chart to measure the distant uncorrected visual acuity. Use 5.0 system to record LogMAR visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>uncorrected visual acuity</measure>
    <time_frame>At 2 weeks</time_frame>
    <description>Use standard LogMAR chart to measure the distant uncorrected visual acuity. Use 5.0 system to record LogMAR visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>uncorrected visual acuity</measure>
    <time_frame>At 1 month</time_frame>
    <description>Use standard LogMAR chart to measure the distant uncorrected visual acuity. Use 5.0 system to record LogMAR visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>uncorrected visual acuity</measure>
    <time_frame>At 3 months</time_frame>
    <description>Use standard LogMAR chart to measure the distant uncorrected visual acuity. Use 5.0 system to record LogMAR visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>uncorrected visual acuity</measure>
    <time_frame>At 6 months</time_frame>
    <description>Use standard LogMAR chart to measure the distant uncorrected visual acuity. Use 5.0 system to record LogMAR visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>uncorrected visual acuity</measure>
    <time_frame>At 9 months</time_frame>
    <description>Use standard LogMAR chart to measure the distant uncorrected visual acuity. Use 5.0 system to record LogMAR visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>uncorrected visual acuity</measure>
    <time_frame>At 12 months/final visit</time_frame>
    <description>Use standard LogMAR chart to measure the distant uncorrected visual acuity. Use 5.0 system to record LogMAR visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The dioptric power of subject</measure>
    <time_frame>At Baseline</time_frame>
    <description>Measure dioptric power (subjective dioptric power): include spherical power, cylindrical power, and cylindrical axis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The dioptric power of subject</measure>
    <time_frame>At 1 day</time_frame>
    <description>Measure dioptric power (subjective dioptric power): include spherical power, cylindrical power, and cylindrical axis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The dioptric power of subject</measure>
    <time_frame>At 1 week</time_frame>
    <description>Measure dioptric power (subjective dioptric power): include spherical power, cylindrical power, and cylindrical axis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The dioptric power of subject</measure>
    <time_frame>At 2 weeks</time_frame>
    <description>Measure dioptric power (subjective dioptric power): include spherical power, cylindrical power, and cylindrical axis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The dioptric power of subject</measure>
    <time_frame>At 1 month</time_frame>
    <description>Measure dioptric power (subjective dioptric power): include spherical power, cylindrical power, and cylindrical axis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The dioptric power of subject</measure>
    <time_frame>At 3 months</time_frame>
    <description>Measure dioptric power (subjective dioptric power): include spherical power, cylindrical power, and cylindrical axis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The dioptric power of subject</measure>
    <time_frame>At 6 months</time_frame>
    <description>Measure dioptric power (subjective dioptric power): include spherical power, cylindrical power, and cylindrical axis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The dioptric power of subject</measure>
    <time_frame>At 9 months</time_frame>
    <description>Measure dioptric power (subjective dioptric power): include spherical power, cylindrical power, and cylindrical axis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The dioptric power of subject</measure>
    <time_frame>At 12 months/final visit</time_frame>
    <description>Measure dioptric power (subjective dioptric power): include spherical power, cylindrical power, and cylindrical axis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relevant important parameters of corneal topography of subject</measure>
    <time_frame>At Baseline</time_frame>
    <description>The corneal topographer is used for measurement, and the relevant parameters include: corneal curvature on the steep meridian Ks, corneal curvature on the flat meridian Kf, and corneal astigmatism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relevant important parameters of corneal topography of subject</measure>
    <time_frame>At 1 day</time_frame>
    <description>The corneal topographer is used for measurement, and the relevant parameters include: corneal curvature on the steep meridian Ks, corneal curvature on the flat meridian Kf, and corneal astigmatism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relevant important parameters of corneal topography of subject</measure>
    <time_frame>At 1 week</time_frame>
    <description>The corneal topographer is used for measurement, and the relevant parameters include: corneal curvature on the steep meridian Ks, corneal curvature on the flat meridian Kf, and corneal astigmatism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relevant important parameters of corneal topography of subject</measure>
    <time_frame>At 2 weeks</time_frame>
    <description>The corneal topographer is used for measurement, and the relevant parameters include: corneal curvature on the steep meridian Ks, corneal curvature on the flat meridian Kf, and corneal astigmatism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relevant important parameters of corneal topography of subject</measure>
    <time_frame>At 1 month</time_frame>
    <description>The corneal topographer is used for measurement, and the relevant parameters include: corneal curvature on the steep meridian Ks, corneal curvature on the flat meridian Kf, and corneal astigmatism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relevant important parameters of corneal topography of subject</measure>
    <time_frame>At 3 months</time_frame>
    <description>The corneal topographer is used for measurement, and the relevant parameters include: corneal curvature on the steep meridian Ks, corneal curvature on the flat meridian Kf, and corneal astigmatism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relevant important parameters of corneal topography of subject</measure>
    <time_frame>At 6 months</time_frame>
    <description>The corneal topographer is used for measurement, and the relevant parameters include: corneal curvature on the steep meridian Ks, corneal curvature on the flat meridian Kf, and corneal astigmatism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relevant important parameters of corneal topography of subject</measure>
    <time_frame>At 9 months</time_frame>
    <description>The corneal topographer is used for measurement, and the relevant parameters include: corneal curvature on the steep meridian Ks, corneal curvature on the flat meridian Kf, and corneal astigmatism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relevant important parameters of corneal topography of subject</measure>
    <time_frame>At 12 months/final visit</time_frame>
    <description>The corneal topographer is used for measurement, and the relevant parameters include: corneal curvature on the steep meridian Ks, corneal curvature on the flat meridian Kf, and corneal astigmatism.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Paragon CRT®100 Contact Lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will wear the Paragon CRT®100 lens with a follow up for no less than 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paragon CRT®100 Contact Lens</intervention_name>
    <description>Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.</description>
    <arm_group_label>Paragon CRT®100 Contact Lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient contact lens refraction should fit within the available parameters of the
             study lenses (spherical power within -4.00D and the cylinder power within 1.50D).

          2. Is willing to comply with the wear and visit schedule.

          3. Is willing to participate and signed the informed consent form.

        Exclusion Criteria:

          1. Age under 8 years old

          2. Any ocular abnormalities, undergone corneal surgery, or history of ocular trauma,
             active corneal infections (corneal inflammation), corneal curvature less than 40.00D
             or more than 46.00D

          3. Best corrected visual acuity less than 1.0D

          4. Pregnant, lactating or near-pregnancy

          5. The eye has the following conditions:

               1. Acute and subacute inflammations or infection of the anterior segment of the eye

               2. Any eye disease, injury, or abnormality that affects the cornea, conjunctiva or
                  eyelids, e.g. dacryocystitis, conjunctivitis, blepharitis and other inflammation,
                  glaucoma, etc.

               3. Severe insufficiency of tears (TBUT≤5s).

               4. Allergy to any ingredient, such as mercury or thimerosal, in a solution which is
                  to be used to care

               5. Any active corneal infection (bacterial, fungal or viral).

          6. Manifested strabismus

          7. Abnormal intra-ocular pressure

          8. Suffering from systemic diseases, resulting in low immunity, or affecting corneal
             re-shaping (such as acute and chronic sinusitis, diabetes, Down syndrome, rheumatoid
             arthritis, mental patients, etc.)

          9. Under medications or long-term medications that lead to dry eye with clinical signs or
             affects vision and corneal curvature.

         10. Examination result indicate any contraindication or not suitable for OrthoK lens wear

         11. Participated in pharmaceutical clinical study 3 months before the date of the
             screening or participated any other medical devices research study within 30 days of
             the screening

         12. Only eye fulfills inclusion criteria

         13. History of any ocular operations

         14. Unable to follow investigator's instruction

         15. Any other condition not suitable for the study per investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang Jun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Eye Hospital of Wenzhou Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qu Xiao Mei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye &amp; ENT Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yang Zhi Kuan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changsha Aier Eye Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Li Hua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Vega, OD, MSc</last_name>
    <phone>9256402964</phone>
    <email>jvega2@coopervision.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changsha Aier Eye Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Zhikuan, MD</last_name>
      <phone>133 8007 1988</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye &amp; ENT Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qu Xiaomei, MD</last_name>
      <phone>137 6066 4837</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Eye Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Li Hua</last_name>
      <phone>136 5180 3988</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Eye Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Jun</last_name>
      <phone>135 0651 1080</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

